Danenberg Noam 4

4 · Wize Pharma, Inc. · Filed Apr 23, 2019

Form 4

Period: 2019-04-21

Chief Operating Officer

Transactions

Purchase
Series A Warrants
2019-04-21+125,000→ 125,000 total
Exercise: $1.10From: 2019-04-21→ Common Stock (125,000 underlying)
Purchase
Common Stock
2019-04-21$1.00/sh+125,000$125,000→ 165,100 total
Purchase
Investment Rights
2019-04-21+94,382→ 94,382 total(indirect: See footnote)
Exercise: $1.33From: 2019-04-21Exp: 2019-11-30→ Common Stock (94,382 underlying)
Purchase
Series B Warrants
2019-04-21+125,000→ 125,000 total
Exercise: $1.00From: 2019-04-21→ Common Stock (125,000 underlying)
Purchase
Convertible Loans
2019-04-21+265,531→ 265,531 total(indirect: See footnote)
Exercise: $1.11Exp: 2019-05-31→ Common Stock (265,531 underlying)

Footnotes (6)

[F1]Issuable upon the conversion of the convertible loans under the January 19, 2017 Loan Agreement (the "Loan Agreement") by and among the Issuer and Ridge Valley Corporation, among others. The Convertible Loans may be converted at any time.
[F2]Mr. Danenberg waived a debt owed to him by Ridge Valley Corporation as consideration for these derivative securities.
[F3]Held by Mr. Danenberg's wholly-owned company Mobigo Inc.
[F4]The Series A Warrants expire sixty (60) months after October 23, 2018.
[F5]Purchased together with the 125,000 shares of Common Stock described in Table I for total purchase price of $125,000.
[F6]The Series B Warrants expire twenty (20) days following the later of (i) the public announcement of Phase II clinical data for LO2A or (ii) six (6) months following October 23, 2018.

Documents

1 file